As PD-(L)1 dis­rup­tors suf­fer set­backs, Check­point touts an­oth­er win

FDA of­fi­cials put a dent in some bio­phar­mas’ quest to dis­rupt PD-(L)1 pric­ing, as many had at­tempt­ed to shut­tle through drugs us­ing da­ta from sin­gle-coun­try tri­als. But Check­point Ther­a­peu­tics is con­tin­u­ing to build out a case for its own check­point in­hibitor, and ap­pears to be suf­fer­ing no such set­backs.

The Mass­a­chu­setts biotech said Thurs­day that an in­ter­im read­out for its an­ti-PD-L1 an­ti­body cosi­be­limab in­duced re­spons­es in 17 of 31 pa­tients with lo­cal­ly ad­vanced cu­ta­neous squa­mous cell car­ci­no­ma, good for a 54.8% ORR. Check­point hopes to add this in­di­ca­tion as a sec­ond la­bel to its FDA ap­pli­ca­tion when it sub­mits lat­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER